Sort
48,018 grants matching “immunotherapy”
A therapeutic Fc gamma Fel d1 chimeric protein vaccine to treat cat allergy
$1,000,000Nolan Sigal · Tunitas Therapeutics, Inc. · R44 · FY2012 · AI
Development of a Therapeutic SAPNANO-ESO Vaccine for Prostate Cancer
$1,000,000Yicheng Wang · Immunova Therapeutics, Llc · R44 · FY2023 · CA
A therapeutic Fc gamma Fel d1 chimeric protein vaccine to treat cat allergy
$1,000,000Nolan Sigal · Tunitas Therapeutics, Inc. · R44 · FY2014 · AI
Therapy and Prophylaxis for Genital Tract Infection
$1,000,000Dominick Auci · Therapyx, Inc. · SB1 · FY2023 · AI
Next Generation Autologous TIL Cancer Therapy: Development of GMP manufacturing process
$1,000,000Rene Gonzalez · Trampoline Pharma, Inc. · R44 · FY2022 · CA
Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma
$1,000,000Evan Charles Unger · Nuvox Pharma, Llc · R44 · FY2017 · CA
Novel immunotherapy against MOG antibody disease
$1,000,000Weston Daniel · Evoq Therapeutics, Inc. · R44 · FY2024 · TR
Therapy and Prophylaxis for Genital Tract Infection
$1,000,000Dominick Auci · Therapyx, Inc. · SB1 · FY2025 · AI
SIRPant Technology for anti-Cancer Immunity
$1,000,000Nathanael McCurley · Sirpant Immunotherapeutics, Inc. · R42 · FY2023 · CA
Programming Metabolically Fit TILs for Immunotherapy
$1,000,000Shikhar Mehrotra · Lipo-Immuno Tech, Llc · R42 · FY2024 · CA
Recombinant yeast vaccines for sensitive and drug-resistant M. tuberculosis
$1,000,000Timothy Rodell · Globeimmune, Inc. · R01 · FY2013 · AI
Riluzole Prodrugs for Melanoma and ALS
$1,000,000Allen Bernard Reitz · Fox Chase Chemical Diversity Center, Inc · R44 · FY2020 · CA
Programming Metabolically Fit TILs for Immunotherapy
$1,000,000Shikhar Mehrotra · Lipo-Immuno Tech, Llc · R42 · FY2023 · CA
CHRONIC LYMPHOCYTIC LEUKEMIA RESEARCH CONSORTIUM
$1,000,000University Of California San Diego · P01 · FY2005 · CA
Non-Activated Natural Killer Cell Engineering For Enhanced Cytotoxic Potential
$1,000,000Michael Chiu · Kytopen Corp · R44 · FY2025 · AI
Development of GPER Agonists as Cancer Therapeutics
$1,000,000Tina Garyantes · Linnaeus Therapeutics, Llc · R44 · FY2019 · CA
Preclinical and IND enabling studies for treatment of advanced lung cancer and other cancers metastatic to lung by pulmonary delivery of engineered Influenza A Virus (eIAV)
$1,000,000Mallikarjun Srivatsan · Accurius Therapeutics, Inc. · R44 · FY2024 · CA
Next Generation Autologous TIL Cancer Therapy: Development of GMP manufacturing process
$1,000,000Richard C Duke · Trampoline Pharma, Inc. · R44 · FY2023 · CA
Monoclonal Antibody Cocktail for Treatment of Marburg Virus Disease
$1,000,000M. Javad Aman · Abvacc, Inc. · R44 · FY2025 · AI
Recombinant yeast vaccines for sensitive and drug-resistant M. tuberculosis
$1,000,000Timothy Rodell · Globeimmune, Inc. · R01 · FY2015 · AI
First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy
$1,000,000Pan Zheng · Oncoc4, Inc. · R44 · FY2021 · CA
Guide RNA manufacturing capabilities for platform in vivo base editing therapies for metabolic liver diseases
$1,000,000William H. Peranteau · Children'S Hosp Of Philadelphia · U19 · FY2025 · NS
Recombinant yeast vaccines for sensitive and drug-resistant M. tuberculosis
$1,000,000Timothy Rodell · Globeimmune, Inc. · R01 · FY2014 · AI
Immunotherapy of MRSA Osteomyelitis
$1,000,000M. Javad Aman · Integrated Biotherapeutics, Inc. · R44 · FY2021 · AI
A parallelized computational microscope platform for high-throughput live imaging of patient-derived organoids
$1,000,000Mark Harfouche · Ramona Optics, Inc. · R44 · FY2025 · CA